Trials / Recruiting
RecruitingNCT06044857
PSMA PET Response Guided SabR in High Risk Pca
Phase IB Study of Personalized Ultrahypofractionated Stereotactic Ablative Radiotherapy of High Risk PROstate Cancer Guided by PET PSMA (68Ga PMSA-11; Ilucix) Response (PULSAR ProPhet)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68-Ga PSMA11 | Will be injected/assessed in line with its FDA label. |
Timeline
- Start date
- 2024-03-07
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2023-09-21
- Last updated
- 2026-04-14
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06044857. Inclusion in this directory is not an endorsement.